|
|
Article: The C1q Binding Site on Rituxan Has Been Mapped.
- Article from:
- Immunotherapy Weekly
- Article date:
- June 4, 2000
CopyrightCOPYRIGHT 2000 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2000 JUN 4 - (NewsRx.com) --
Researchers from the United States have mapped the C1q binding site on Rituxan.
"Rituxan (Rituximab) is a chimeric monoclonal antibody (MAb) with human IgG1 constant domains used in the therapy of non-Hodgkin's B-cell lymphomas," wrote E.E. Idusogie and colleagues, Genentech Inc., California. "This antibody (Ab) targets B cells by binding to the cell-surface receptor, CD20. In our investigation of the mechanism of B-cell depletion mediated by Rituximab, we first constructed mutants of Rituximab defective in complement activation but with all other effector functions intact."
Idusogie et al. published their study ...